Loading…
Reported covered position: Intern Senator Casey
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
| REVAGENIX, INC. |
| 8 |
| 2025–2026 |
| PSYCHEDELIC MEDICINE COALITION | 7 | 2023–2024 |
| COHERUS BIOSCIENCES | 6 | 2023–2024 |
| BRIGHT PATH LABORATORIES, INC. | 4 | 2026 |
| FOUNDATION FIGHTING BLINDNESS | 2 | 2023 |
| PKX BIO | 2 | 2026 |
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
eek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
2026 · third_quarter · Q3
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PKX BIO via THE CONAFAY GROUP, LLC
2026 · third_quarter · 3T
Advocate for funding for research and development for pain solutions.
Advocate for funding for research and development for pain solutions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKX BIO via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocate for funding for research and development for pain solutions.
Advocate for funding for research and development for pain solutions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Policies that promote domestic pharmaceutical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY27 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRIGHT PATH LABORATORIES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · RR
Policies that promote domestic pharmaceutical manufacturing.
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · third_quarter · 3T
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Seek approval for regulatory support; FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Seek approval for regulatory support; FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · RR
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Education and advocacy for novel brain health treatments.
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Advocacy for medical countermeasure funding and support
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · second_quarter · 2T
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2024 · second_quarter · 2T
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Seek approval for regulatory support; FY24 appropriations; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; FY24 appropriations; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · RR
Medical countermeasure management.
Medical countermeasure management.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Seek approval for regulatory support; HR3437; Loans Act.
Seek approval for regulatory support; HR3437; Loans Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · second_quarter · RR
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION FIGHTING BLINDNESS via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Education & advocacy for mechanisms to spur development of clinical trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Seek approval for regulatory support; HR3437; Loans Act.
Seek approval for regulatory support; HR3437; Loans Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · first_quarter · RR
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
FOUNDATION FIGHTING BLINDNESS via THE CONAFAY GROUP, LLC
2023 · first_quarter · RR
Education & advocacy for mechanisms to spur development of clinical trials.
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Seek approval for regulatory support; HR3437; Loans Act.
Seek approval for regulatory support; HR3437; Loans Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2022 · third_quarter · Q3
Seek approval for regulatory support; HR3437; Loans Act
seek approval for regulatory support; HR3437; Loans Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2022 · third_quarter · Q3
Strengthening the medical supply chain
Strengthening the medical supply chain
Strengthening the medical supply chain
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2022 · second_quarter · Q2
Seek approval for regulatory support; HR3437; Loans Act
seek approval for regulatory support; HR3437; Loans Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2022 · second_quarter · Q2
Strengthening the medical supply chain
Strengthening the medical supply chain
Strengthening the medical supply chain
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE